Latest News

doctor supporting patient
Study Documents HCPs’ Experiences of a Mandatory Switch to Inform Future Transitions

December 2nd 2023

A survey explores the experiences of health care providers (HCP) throughout the transition process following a mandatory switch from the adalimumab originator (Humira) to a biosimilar in New Zealand in 2022.

HHS on a phone | Image credit: Timon - stock.adobe.com
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain

November 28th 2023

Image credit: Aliaksandr Marko | stock.adobe.com
Confusion Persists Around the Interchangeability Designation for Biosimilars

November 23rd 2023

injectable pens
BioRationality: FDA Publishes Results of First Meta-Analysis to Conclude All Biosimilars Are Interchangeable

November 20th 2023

Eye on Pharma banner
Eye on Pharma: Denosumab Biosimilar Data; COA Forms New Committee; IGBA and WHO Collaborate

November 8th 2023

More News

© 2023 MJH Life Sciences

All rights reserved.